Cargando…

Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient

Introduction. Hepatitis C virus (HCV) infection continues to represent a poor prognostic factor in kidney transplant (KTx) patients. New direct-acting antiviral agents (DAA) have dramatically changed the therapy management for HCV, showing promising results in terms of sustained virologic response....

Descripción completa

Detalles Bibliográficos
Autores principales:	Varotti, Giovanni, Dodi, Ferdinando, Paoletti, Ernesto, Bruno, Andrea, Fontana, Iris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684507/ https://www.ncbi.nlm.nih.gov/pubmed/34931152 http://dx.doi.org/10.1155/2021/1948560

Ejemplares similares

Fatal Donor-Derived Carbapenem-Resistant Klebsiella pneumoniae Infection in a Combined Kidney-Pancreas Transplantation
por: Varotti, Giovanni, et al.
Publicado: (2016)

Predictive Potential of Flow Cytometry Crossmatching in Deceased Donor Kidney Transplant Recipients Subjected to Peritransplant Desensitization
por: Osickova, Klara, et al.
Publicado: (2021)

Prognostic Impact of Peritransplant Serum Sodium Concentrations in Liver Transplantation
por: Mihaylov, Plamen, et al.
Publicado: (2019)

Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation
por: Hirao, Hirofumi, et al.
Publicado: (2021)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Changing Population of Liver Transplant Recipients in the Era of Direct-acting Antiviral Therapy
por: Xie, Chencheng, et al.
Publicado: (2020)

Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience
por: Alkadi, Mohamad M., et al.
Publicado: (2020)

Nutritional status and hyperglycemia in the peritransplant period: a review of associations with parenteral nutrition and clinical outcomes
por: Verdi Schumacher, Marina, et al.
Publicado: (2017)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality
por: Goetsch, Michael R., et al.
Publicado: (2020)

Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study
por: Darema, Maria, et al.
Publicado: (2020)

Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era
por: Farmakiotis, Dimitrios, et al.
Publicado: (2020)

Antivirals for COVID-19 in Solid Organ Transplant Recipients
por: Laracy, Justin C., et al.
Publicado: (2020)

The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients
por: Gottlieb, Robert L., et al.
Publicado: (2018)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study
por: Chen, Keliang, et al.
Publicado: (2017)

Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis
por: Liu, Jiaye, et al.
Publicado: (2019)

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
por: Sharma, Sourabh, et al.
Publicado: (2018)

“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era
por: Cotter, Thomas G., et al.
Publicado: (2021)

Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients
por: Gambato, Martina, et al.
Publicado: (2023)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
por: Wellington, Jennifer, et al.
Publicado: (2021)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Peritransplant Varicosis After Simultaneous Pancreas and Kidney Transplantation Is an Uncommon Cause of Late-Onset and Recurrent Gastrointestinal Bleeding
por: Pfister, Matthias, et al.
Publicado: (2023)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios
por: Goetsch, Michael R., et al.
Publicado: (2017)

Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era
por: Zuckerman, Autumn, et al.
Publicado: (2018)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
por: Toyoda, Mieko, et al.
Publicado: (2017)

572. Antiviral Toxicities Among Pediatric Solid Organ Transplant Recipients
por: Downes, Kevin J, et al.
Publicado: (2020)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil
por: Silva, Isabella Patrícia Lima, et al.
Publicado: (2021)

Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma
por: Nagao, Yumiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_244vvue4vt7t0kc8cv8epllp3d